2-chloro-N-(1-methylpiperidin-4-yl)quinazolin-4-amine | 1394248-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-N-(1-methylpiperidin-4-yl)quinazolin-4-amine
• 英文别名: 2-chloro-N-(1-methyl-4-piperidyl)quinazolin-4-amine
• CAS: 1394248-30-6
• 化学式: C₁₄H₁₇ClN₄
• 分子量: 276.769
• InChiKey: FYDJAXRBDTVOBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-N-(1-methylpiperidin-4-yl)quinazolin-4-amine 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 2-hydrazinyl-N-(1-methylpiperidin-4-yl)quinazolin-4-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents

  摘要：

  Two series of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives were synthesized and evaluated for their cytotoxicity against H-460, HT-29, HepG2 and SGC-7901 cancer cell lines in vitro. Most compounds displayed moderate to excellent activity, with IC50 values ranging from 0.015 to 4.09 mu M against all tested cell lines, respectively. The most promising compound 9p (E)-2-(24(1-(2,3-dichlorobenzyl)-1H-imidazol-2-yl)methylene)hydrazinyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine with IC50 values of 0.031 mu M, 0.015 mu M, 0.53 mu M and 0.58 mu M, which was 4- to 224 times more active than references 10 and Iressa, had emerged as a lead for further structural modifications. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.05.039
• 作为产物：
  描述：

  邻氨基苯甲酸 在 三乙胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 18.25h， 生成 2-chloro-N-(1-methylpiperidin-4-yl)quinazolin-4-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents

  摘要：

  Two series of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives were synthesized and evaluated for their cytotoxicity against H-460, HT-29, HepG2 and SGC-7901 cancer cell lines in vitro. Most compounds displayed moderate to excellent activity, with IC50 values ranging from 0.015 to 4.09 mu M against all tested cell lines, respectively. The most promising compound 9p (E)-2-(24(1-(2,3-dichlorobenzyl)-1H-imidazol-2-yl)methylene)hydrazinyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine with IC50 values of 0.031 mu M, 0.015 mu M, 0.53 mu M and 0.58 mu M, which was 4- to 224 times more active than references 10 and Iressa, had emerged as a lead for further structural modifications. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.05.039

文献信息

• [EN] BROAD SPECTRUM ANTI-CANCER COMPOUNDS<br/>[FR] COMPOSÉS ANTICANCÉREUX À LARGE SPECTRE
  申请人：UNIV CALIFORNIA

  公开号：WO2021076617A1

  公开（公告）日：2021-04-22

  Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

  本文描述了用于治疗癌症的化合物和使用方法。该公开涉及抑制m6A编写酶（例如，甲基转移酶类3（Mettl3或MT-A70）或甲基转移酶类14（Mettl14））、m6Am编写酶（例如，磷酸化CTD相互作用因子I（PCIF 1）或Mettl3/14）、m6A擦除酶（例如，脂肪质量和肥胖相关蛋白（FTO）或ALKB同源物5（ALKBH5））、m6Am擦除酶（例如，FTO）、m6A读取器（例如，YTH结构域含家族蛋白（YTHs））、YTF结构域家族成员1（YTHDF 1）、YTF结构域家族成员2（YTHDF 2）、YTF结构域家族成员3（YTHDF 3）或酪氨酸蛋白磷酸酶非受体型2（PTPN2）等化学实体（例如，小发夹RNA（shRNAs）、微RNA（miRNAs）、小干扰RNA（siRNAs）、小分子抑制剂、反义核酸、肽、病毒、CRISPR-sgRNAs或其组合）。
• Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity
  作者：Trent D. Ashton、Anna Ngo、Paola Favuzza、Hayley E. Bullen、Maria R. Gancheva、Ornella Romeo、Molly Parkyn Schneider、Nghi Nguyen、Ryan W.J. Steel、Sandra Duffy、Kym N. Lowes、Helene Jousset Sabroux、Vicky M. Avery、Justin A. Boddey、Danny W. Wilson、Alan F. Cowman、Paul R. Gilson、Brad E. Sleebs

  DOI：10.1016/j.bioorg.2021.105359

  日期：2021.12

  Plasmodium parasites. Emerging resistance against current antimalarial therapeutics has engendered the need to develop antimalarials with novel structural classes. We recently described the identification and initial optimization of the 2-anilino quinazoline antimalarial class. Here, we refine the physicochemical properties of this antimalarial class with the aim to improve aqueous solubility and metabolism

  疟疾是一种由疟原虫引起的毁灭性疾病。对当前抗疟疗法的新出现的抗药性导致需要开发具有新结构类别的抗疟药。我们最近描述了 2-苯胺基喹唑啉类抗疟药的鉴定和初步优化。在这里，我们改进了这种抗疟药的物理化学性质，目的是提高水溶性和新陈代谢，并减少不良混杂。我们展示了此类的物理化学特性与无性寄生虫活性和人类细胞细胞毒性之间的复杂平衡。我们进行了结构修饰，改善了 LipE、水溶性和体外代谢，同时保留了速效恶性疟原虫无性阶段活动。先导化合物表现出对诺氏疟原虫的等效活性，并且不倾向于临床使用的抗疟药的耐药机制。优化后的化合物对早期配子体表现出适度的活性，但对红细胞前肝寄生虫没有活性。令人困惑的是，与早期对 2-苯胺基喹唑啉类的研究相比，在伯氏疟原虫小鼠疟疾模型中，安装在化合物中的精细物理化学特性并未提高口服功效。本研究为进一步开发这种抗疟药提供了框架。
• Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity
  作者：Paul R. Gilson、Cyrus Tan、Kate E. Jarman、Kym N. Lowes、Joan M. Curtis、William Nguyen、Adrian E. Di Rago、Hayley E. Bullen、Boris Prinz、Sandra Duffy、Jonathan B. Baell、Craig A. Hutton、Helene Jousset Subroux、Brendan S. Crabb、Vicky M. Avery、Alan F. Cowman、Brad E. Sleebs

  DOI：10.1021/acs.jmedchem.6b01673

  日期：2017.2.9

  Novel antimalarial therapeutics that target multiple stages of the parasite lifecycle are urgently required to tackle the emerging problem of resistance with current drugs. Here, we describe the optimization of the 2-anilino quinazoline class as antimalarial agents. The class, identified from publicly available antimalarial screening data, was optimized to generate lead compounds that possess potent

  迫切需要针对寄生虫生命周期多个阶段的新型抗疟疾疗法，以解决当前药物出现的耐药性问题。在这里，我们描述了2-苯胺基喹唑啉类作为抗疟剂的优化。从可公开获得的抗疟疾筛查数据确定的类别进行了优化，以生成对恶性疟原虫寄生虫具有有效抗疟疾活性的先导化合物，其与已知的抗疟疾，氯喹和甲氟喹相当。在优化过程中，我们定义了活性所必需的功能，并改善了体外代谢和溶解度。所得的铅化合物对恶性疟原虫的多药耐药菌株具有有效的活性。并在无性繁殖的环状期和寄生虫细胞期将寄生虫捕杀。最后，我们显示了在4天的疟疾疾病负担小鼠模型中，这些先导化合物具有口服有效作用。
• Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents
  作者：Nan Jiang、Xin Zhai、Yanfang Zhao、Yajing Liu、Baohui Qi、Haiyan Tao、Ping Gong

  DOI：10.1016/j.ejmech.2012.05.039

  日期：2012.8

  Two series of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives were synthesized and evaluated for their cytotoxicity against H-460, HT-29, HepG2 and SGC-7901 cancer cell lines in vitro. Most compounds displayed moderate to excellent activity, with IC50 values ranging from 0.015 to 4.09 mu M against all tested cell lines, respectively. The most promising compound 9p (E)-2-(24(1-(2,3-dichlorobenzyl)-1H-imidazol-2-yl)methylene)hydrazinyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine with IC50 values of 0.031 mu M, 0.015 mu M, 0.53 mu M and 0.58 mu M, which was 4- to 224 times more active than references 10 and Iressa, had emerged as a lead for further structural modifications. (C) 2012 Elsevier Masson SAS. All rights reserved.